Table 1 summarizes the inhibitors targeting NLRP3 inflammasome that have been investigated in pre-clinical or clinical studies, especially in the context of PD and other CNS diseases. Figure 1 indicates the mechanisms of action for the NLRP3 inhibitors discussed in this section. This evidence concerns the gene NLRP3 and Parkinson disease.